

*SPECIAL ARTICLE*

**References to ‘Side-effects of antileprosy drugs in common use’\* (Jopling WH. Editorial, *Lepr Rev* 1983; **54**: 261–70)**

W H JOPLING

389a Holmesdale Road, South Norwood, London SE25 6PN

**Dapsone**

For general reviews of dapsone’s side-effects, see (1) Graham WR. Adverse effects of dapsone. *Int J Dermatol*, 1975; **14**: 494–500; (2) Leading Article. Adverse reactions to dapsone. *Lancet*, 1981; **2**: 184–5.

I. BLOOD

(a) *Haemolysis*

Cream JJ, Scott GL. Anaemia in dermatitis herpetiformis: the role of dapsone-induced haemolysis and malabsorption. *Br J Dermatol*, 1970; **82**: 333–42.

Hutchison HE, Jackson JM, Cassidy P. Drug-induced haemolytic anaemia in dermatitis herpetiformis. *Br J Dermatol*, 1963; **75**: 161–6.

Pengelly CDR. Dapsone-induced haemolysis. *Br Med J*, 1963; **2**: 662–4.

Smith RS, Alexander S. Heinz-body anaemia due to dapsone. *Br Med J*, 1959; **1**: 625–7.

Sritharan V, Bharadwaj VP, Venkatesan K, Girdhar BK. Dapsone-induced hypohaptoglobulinaemia in lepromatous leprosy patients. *Int J Lepr*, 1981; **49**: 307–10.

Stone SP, Goodwin RM. Dapsone-induced jaundice. *Arch Dermatol*, 1978; **114**: 947.

*Haemolysis and G-6-PD deficiency.* Chernov D. Dapsone-induced haemolysis in G6PD deficiency. *JAMA*, 1967; **201**: 144–6. Degowin RL, Eppes RB, Powell RD. The haemolytic effect of diaphenylsulphone (DDS) in normal subjects and those with G6PD deficiency. *Bull WHO*, 1966; **35**: 165–79.

*Haemolysis due to a toxic DDS derivative (DDS-NHOH).* Manfredi G, De Panfilis G, Zampetti M, Allegra F. Studies on dapsone induced haemolytic anaemia. *Br J Dermatol*, 1979; **100**: 427–32.

*Haemolysis due to DDS in breast milk.* Saunders SW, Zone JJ, Foltz RL, Tolman KG, Rollins DE. Haemolytic anaemia induced by dapsone transmitted through breast milk. *Ann Intern Med*, 1982; **96**: 465–6.

(b) *Agranulocytosis*

- Firkin FC, Mariani AF. Agranulocytosis due to dapsone. *Med J Aust*, 1977; **2**: 247–51.
- Levine PH, Weintraub LR. Pseudoleukemia during recovery from dapsone-induced agranulocytosis. *Ann Intern Med*, 1968; **68**: 1060–65.
- McConkey B. Adverse reactions to dapsone. *Lancet*, 1981; **2**: 525.
- McKenna WB, Chalmers AC. Agranulocytosis following dapsone therapy. *Br Med J* 1958; **1**: 324–5.
- Ognibene AJ. Agranulocytosis due to dapsone. *Ann Intern Med*, 1970; **72**: 521–4 (See comments on this paper by Jopling WH. *Ann Intern Med*, 1972; **77**: 153.)
- Weetman RM, Brown MP, Boxer LA, Baehner RL. Oxidant mechanism for sulfone induced agranulocytosis. *Pediatr Res*, 1978; **12**: 476 (Abstract 674).

(c) *Methaemoglobinaemia*

- Alexander JO'D. Dapsone in the treatment of dermatitis herpetiformis. *Lancet*, 1955; **1**: 1201–2.
- Alexander JO'D, Young E, McFadyen T, Fraser NG, Duguid WP, Meredith EM. Absorption and excretion of 35S dapsone in dermatitis herpetiformis. *Br J Dermatol*, 1970; **83**: 620–31.
- Manfredi G, De Panfilis G, Zampetti M, Allegra F. Studies on dapsone induced haemolytic anaemia. 1. Methaemoglobin production and G-6-PD activity in correlation with dapsone dosage. *Br J Dermatol*, 1979; **100**: 427–32.

2. HYPERSENSITIVITY SKIN REACTIONS

- Browne SG, Ridge E. Toxic epidermal necrolysis. *Br Med J*, 1961; **1**: 550–3.
- Dutta RK. Erythema multiforme bullosum due to dapsone. *Lepr India*, 1980; **52**: 306–9.
- Goette DK. Letter in *Arch Dermatol*, 1977; **113**: 1616–17.
- Lal S, Garg BR. Sulphone induced exfoliative dermatitis and hepatitis. *Lepr India*, 1980; **52**: 302–5.
- Leiker DL. The mononucleosis syndrome in leprosy patients treated with sulfones. *Int J Lepr*, 1956; **24**: 402–5.
- Millikan LE, Harrell ER. Drug reactions to the sulfones. *Arch Dermatol*, 1970; **102**: 220–4.
- Potter B, Szymanski FJ, Fretzin D. Erythema elevatum diutinum and sulfone hypersensitivity. *Arch Dermatol*, 1967; **95**: 436–40.

*DDS Syndrome (sulphone syndrome)*. Allday EJ, Barnes J. Toxic effects of diaminodiphenyl sulphone in treatment of leprosy. *Lancet*, 1951; **2**: 205–6.

Frey HM, Gershon AA, Borkowsky W, Bullock WE. Fatal reaction to dapsone during treatment of leprosy. *Ann Intern Med*, 1981; **94**: 777–9.

Tomecki KJ, Catalano CJ. DDS syndrome. *Arch Dermatol*, 1981; **117**: 38–9.

3. FIXED DRUG ERUPTION

Browne SG. A hypermelanotic rash complicating sulphone therapy. *Trans R Soc Trop Med Hyg*, 1959; **53**: 495–505.

4. PERIPHERAL NEUROPATHY

Epstein FW, Bohm M. Dapsone-induced peripheral neuropathy. *Arch Dermatol*, 1976; **112**: 1761–2.

Fredericks EJ, Kugelman TP, Kirsch N. Dapsone-induced motor polyneuropathy. *Arch Dermatol*, 1976; **112**: 1158–60.

- Gehlmann LK, Koller WC, Malkinson FD. Dapsone-induced neuropathy. *Arch Dermatol*, 1977; **113**: 845–6.
- Gutmann L, Martin JD, Welton W. Dapsone motor neuropathy—an axonal disease. *Neurology*, 1976; **26**: 514–16.
- Homeida M, Babikr A, Daneshmend TK. Dapsone-induced optic atrophy and motor neuropathy. *Br Med J*, 1980; **281**: 1180, and 1981; **283**: 311.
- Hubler WR, Solomon H. Neurotoxicity of sulfones. *Arch Dermatol*, 1972; **106**: 598.
- Koller WC, Gehlmann LK, Malkinson FD, Davis FA. Dapsone-induced peripheral neuropathy. *Arch Neurol*, 1977; **34**: 644–6.
- Rapoport AM, Guss SB. Dapsone-induced peripheral neuropathy. *Arch Neurol*, 1972: 184–5.
- Saqueton AC, Lorincz AL, Vick NA, Hamer RD. Dapsone and peripheral motor neuropathy. *Arch Dermatol*, 1969; **100**: 214–17.
- Volden G. Peripheral neuropathy: a side effect of sulphones. *Br Med J*, 1977; **1**: 1193.
- Wyatt EH, Stevens JC. Dapsone induced peripheral neuropathy. *Br J Dermatol*, 1972; **86**: 521–3.

#### 5. PSYCHOSIS

- Murthy KK, Babu KKR. Toxic psychosis after accidental ingestion of dapsone: review and case report. *Lepr India*, 1980; **52**: 443–5.
- Sahu DM. Dapsone induced psychosis—a case report. *Indian J Dermatol*, 1972; **17**: 47–8.
- Verma KC, Singh K, Chowdhary SD. Dapsone toxicity. *J Indian Med Assoc*, 1973; **60**: 255.

#### 6. HYPOALBUMINAEMIA

- Cowan RE, Wright JT. Dapsone and severe hypoalbuminaemia in dermatitis herpetiformis. *Br J Dermatol*, 1981; **104**: 201–4.
- Foster PN, Swan CHJ. Dapsone and fatal hypoalbuminaemia. *Lancet*, 1981; **2**: 806–7.
- Kingham JGC, Swain P, Swarbrick ET, Walker JG, Dawson AM. Dapsone and severe hypoalbuminaemia: a report of two cases. *Lancet*, 1979; **2**: 662–4.
- Young S, Marks JM. Dapsone and severe hypoalbuminaemia. *Lancet*, 1979; **2**: 908–9.

#### 7. NEPHROTIC SYNDROME

- Belmont A. Dapsone-induced nephrotic syndrome. *JAMA*, 1967; **200**: 262–3.

#### 8. RENAL PAPILLARY NECROSIS

- Hoffbrand BI. Dapsone and renal papillary necrosis. *Br Med J*, 1978; **1**: 78.

#### 9. HEPATIC DYSFUNCTION

- Stone SP, Goodwin RM. Dapsone-induced jaundice. *Arch Dermatol*, 1978; **114**: 947.
- N.B. Publications by John Lowe and other leprologists using DDS soon after its introduction in clinical work, and using large doses around 300 mg daily, report various side-effects including severe anaemia, agranulocytosis, exfoliative dermatitis, hepatitis and psychosis: Lowe J, Smith M. *Int J Lepr*, 1949; **17**: 181; Lowe J. *Lancet*, 1950; **1**: 145; Lowe J. *Lancet*, 1951; **1**: 18; Jelliffe DB. *Lancet*, 1951; **1**: 1343; Ramanujam K, Smith M. *Lancet*, 1951; **1**: 21.

**Clofazimine**

For general reviews of clofazimine's side-effects, see (1) Jopling WH. *Lepr Rev*, 1976; **47**: 1-3; (2) Yawalkar SJ, Vischer W. *Lepr Rev*, 1979; **50**:135-44; (3) Moore VJ. *Lepr Rev*, 1983; **54**: 327-35.

**I. SMALL BOWEL SYNDROME**

Atkinson AJ Jr, Sheagren JN, Barba Rubio J, Knight V. Evaluation of B663 in human leprosy. *Int J Lepr*, 1967; **35**: 119-27.

Belaube P, Devaux J, Boutboul R, De Micco C, Pizzi M, Privat Y. Exudative enteropathy due to clofazimine: a case report. *Acta Leprol*, 1982; **88**: 61-7 (in French). Abstracted in *Int J Lepr*, 1983; **51**: 129.

De Bergeyck E, Janssens PG, De Muynck A. Radiological abnormalities of the ileum associated with the use of clofazimine (Lamprene; B663) in the treatment of skin ulceration due to *Mycobacterium ulcerans*. *Lepr Rev*, 1980; **51**: 221-8.

Desikan KV, Ramanujam K, Ramu G, Balakrishnan S. Autopsy findings in a case of lepromatous leprosy treated with clofazimine. *Lepr Rev*, 1975; **46**: 181-9.

Harvey RF, Harman RRM, Black C *et al.* abdominal pain and malabsorption due to tissue deposition of clofazimine (Lamprene) crystals. *Br J Dermatol*, 1977; **97** (Suppl 15): 19.

Jagadeesan K, Visweswaran MK, Iyer KH. Acute abdomen in a patient treated with lamprene. *Int J Surg*, 1975; **60**: 208-9.

Karat ABA. Long-term follow-up of clofazimine (Lamprene) in the management of reactive phases of leprosy. *Lepr Rev*, 1975; **46** (Suppl): 105-9.

Kumar B, Bahadur B, Broor SL, Kaur S, Gangwar DN, Malik AK. Study of toxicity of clofazimine with special reference to structural and functional status of small intestine. *Lepr India*, 1982; **54**: 246-52.

Lal S, Garg BR, Hameedulla A. Gastro-intestinal side effects of clofazimine. *Lepr India*, 1981; **53**: 285-8.

Plock H, Leiker DL. A long term trial with clofazimine in reactive lepromatous leprosy. *Lepr Rev*, 1976; **47**: 25-34.

Ramu G, Iyer CGS. Side effects of clofazimine therapy. *Lepr India*, 1976; **48** (Suppl): 722-31.

**2. EOSINOPHILIC ENTERITIS**

Mason GH, Ellis-Pegler RB, Arthur JF. Clofazimine and eosinophilic enteritis. *Lepr Rev*, 1977; **48**: 175-80.

**3. SPLENIC INFARCTION**

McDougall AC, Horsfall WR, Hede JE, Chaplin AJ. Splenic infarction and tissue accumulation of crystals associated with the use of clofazimine (Lamprene; B663) in the treatment of pyoderma gangrenosum. *Br J Dermatol*, 1980; **102**: 227-30.

**4. REVERSIBLE OCULAR SIDE-EFFECT**

(a) Pigmentation of macula and cornea. Ohman L, Wahlberg I. Ocular side-effects of clofazimine. *Lancet*, 1975; **2**: 934.

(b) Fine brownish lines on cornea. Walinder PE, Gip L, Stempa M. Corneal changes in patients treated with clofazimine. *Br J Ophthal*, 1976; **60**: 526-8.

**Rifampicin**

For a general review of side-effects of rifampicin, see: Girling DJ, Hitze KL. Adverse reactions to rifampicin. *Bull WHO*, 1979; **57**: 45–9.

## I. HEPATIC DYSFUNCTION

Aquinas M, Allan WGL, Horsfall PAL *et al.* Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. *Br Med J*, 1972; **1**: 765–71.

Di Piazza S, Cottone M, Craxi A, Gotto G, Pinzello G, Pagliano L. Severe rifampicin-associated liver failure in patients with compensated cirrhosis. *Lancet*, 1978; **1**: 774.

Girling DJ. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. *Tubercle*, 1978; **59**: 13–32.

Gutman L (Laura). More adverse reactions to rifampicin. *J Antimicrob Chemother*, 1978; **4**: 283.

Kutsukake F, Murakami T, Sasaki Y *et al.* In Japanese, but abstracted in *Excerpta Medica* (Leprosy and Related Subjects) 1983, vol 5, Issue 7, No 972.

Rothwell DL, Richmond DE. Hepatorenal failure with self-initiated intermittent rifampicin therapy. *Br Med J*, 1974; **2**: 481–2.

Tsiricas T, Papasavvas P, Pantazis K, Toumanidis S. Rifampicin hepatitis. In Greek, but abstracted in *Excerpta Medica* (Leprosy and Related Subjects) 1981, vol 3, Issue 4, No 640.

## 2. BLOOD CHANGES

(a) *Thrombocytopenia*

Aquinas M, Allan WGL, Horsfall PAL *et al.* Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. *Br Med J*, 1972; **1**: 765–71.

Blajchman MA, Lowry RC, Pettit JE, Stradling P. Rifampicin-induced immune thrombocytopenia. *Br Med J*, 1970; **3**: 24–6.

Ferguson GC. Rifampicin and thrombocytopenia. *Br Med J*, 1971; **3**: 638.

Galietti F, Poy G, Passera R, Costa M. Rifampicin induced thrombocytopenia: description of a case. In Italian, but abstracted in *Excerpta Medica* (Leprosy & Related Subjects) 1980, vol 2, Issue 2, No 206.

Girling DJ, Fox W. Side effects of intermittent rifampicin. *Br Med J*, 1971; **4**: 231–2.

Hadfield JW. Rifampicin-induced thrombocytopenia. *Postgrad Med J*, 1980; **65**: 59–60.

Poole G, Stradling P, Worledge S. Potentially serious side-effects of high-dose, twice-weekly rifampicin. *Br Med J*, 1971; **3**: 343–7.

(b) *Haemolysis*

Lakshminarayan S, Sahn SA, Hudson LD. Massive haemolysis caused by rifampicin. *Br Med J*, 1973; **2**: 282.

Miyachi S, Kosuda T, Hisatomi T *et al.* A case of severe haemolytic anaemia and acute renal failure caused by RFP. In Japanese, but abstracted in *Excerpta Medica* (Leprosy & Related Subjects) 1983, vol 5, Issue 7, No 973.

(c) *Neutropenia/Agranulocytosis*

Jenkins PF, Williams TD, Campbell IA. Neutropenia with each standard antituberculosis drug in the same patient. *Br Med J*, 1980; **280**: 1069–70.

(d) *Eosinophilia*

- Lee M, Berger HW. Eosinophilia caused by rifampicin. *Chest*, 1980; **77**: 579.  
Mungall IPF, Standing VF. Eosinophilia caused by rifampicin. *Chest*, 1978; **74**: 321–2.  
Nigam P, Goyal BM, Saxena HN. Eosinophilia as a result of rifampicin therapy. *J Indian Med Assoc*, 1981; **77**: 158–9.

3. PSYCHOSIS

- Jeanes CWL, Jessamine AG, Eidus L. Treatment of chronic drug-resistant pulmonary tuberculosis with rifampicin and ethambutol. *Can Med Ass J*, 1972; **106**: 884–8.  
Pratt TH. Rifampicin-induced organic brain syndrome. *JAMA*, 1979; **241**: 2421–2.

4. OSTEOMALACIA

- Brodie MJ, Boobis AR, Dollery CT *et al.* Rifampicin and Vitamin D metabolism. *Clin Pharm Ther*, 1980; **27**: 810–14.  
Shah SC, Sharma RK, Chittle H, Chittle AR. Rifampicin induced osteomalacia. *Tubercle*, 1981; **62**: 207–9.

5. HYPERSENSITIVITY SKIN REACTIONS

- Aquinas M, Allan WGL, Horsfall PAL *et al.* Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. *Br Med J*, 1972; **1**: 765–71.  
Gange RW, Rhodes EL, Edwards CO, Powell MEA. Pemphigus induced by rifampicin. *Br J Dermatol*, 1976; **95**: 445–8.  
Millar JW. Rifampicin-induced porphyria cutanea tarda. *Br J Dis Chest*, 1980; **74**: 405–8.  
Nigam P, Dayal SG, Goyal BM. Erythema multiforme bullosum due to rifampicin. *Lepr India*, 1979; **51**: 249–51.  
Nwokolo U. Acneiform lesions in combined rifampicin treatment in Africans. *Br Med J*, 1974; **3**: 473.  
Nyirenda R, Gill GV. Stevens-Johnson syndrome due to rifampicin. *Br Med J*, 1977; **2**: 1189.

6. HAEMORRHAGIC DISEASE OF THE NEWBORN

- Hoyer PF, Ehrich JHH, Barthels M. Neonatal haemorrhagic disease in a newborn after rifampicin treatment during pregnancy. In German, but abstracted in *Excerpta Medica* (Leprosy & Related Subjects) 1982, vol 4, Issue 8, No 1052.  
Lissens J, Shih H, Verbist L *et al.* Haemorrhagic disease in the infant of a mother treated with rifampicin. In Dutch, but abstracted in *Excerpta Medica* (Leprosy & Related Subjects) 1984, vol 6, Issue 1, No 50.

7. 'FLU' SYNDROME

- Girling DJ, Fox W. Side effects of intermittent rifampicin. *Br Med J*, 1971; **4**: 231–232.  
Girling DJ. Adverse reactions to rifampicin in antituberculosis regimens. *J Antimicrob Chemother*, 1977; **3**: 115–32.  
Poole G, Stradling P, Worledge S. Potentially serious side-effects of high-dose, twice-weekly rifampicin. *Br Med J*, 1971; **3**: 343–7.

## 8. RENAL FAILURE

- Bansal VK, Bennett D, Molnar Z. Prolonged renal failure after rifampicin. *Am Rev Respir Dis*, 1977; **116**: 137–40.
- Campese VM, Marzullo F, Schena FP, Coratelli P. Acute renal failure during intermittent rifampicin therapy. *Nephron*, 1973; **10**: 256–61.
- Davison AG, Empey DW. Acute renal failure following reintroduction of rifampicin after a prolonged interval. *Br J Dis Chest*, 1981; **75**: 103–4.
- Flynn CT, Rainford DJ, Hope E. Acute renal failure and rifampicin: danger of unsuspected intermittent dosage. *Br Med J*, 1974; **2**: 482.
- Gabow PA, Lacher JW, Neff TA. Tubulointerstitial and glomerular nephritis associated with rifampicin. Report of a case. *JAMA*, 1976; **235**: 2517–18.
- Kleinknecht D, Homberg JC, Decroix G. Acute renal failure after rifampicin. *Lancet*, 1972; **1**: 1238–9.
- Mattson K, Riska H, Forsstrom J, Kock B. Acute renal failure following rifampicin administration. *Scand J Resp Dis*, 1974; **55**: 291–7.
- Nessi R, Bonoldi GL, Redaelli B, Di Filippo G. Acute renal failure after rifampicin: a case report and survey of the literature. *Nephron*, 1976; **16**: 148–59.
- Neugarten J, Gallo GR, Baldwin DS. Rifampicin-induced nephrotic syndrome and acute interstitial nephritis. *Am J Nephrol*, 1983; **3**: 38–42.
- Poole G, Stradling P, Worledge S. Potentially serious side-effects of high-dose twice-weekly rifampicin. *Br Med J*, 1971; **3**: 343–7. (The same paper appears in *Postgrad Med J*, 1971; **47**: 742–7).
- Qunibi WY, Godwin J, Eknayan G. Toxic nephropathy during continuous rifampicin therapy. *South Med J*, 1980; **73**: 791–2.
- Rothwell DL, Richmond DE. Hepatorenal failure with self-initiated intermittent rifampicin therapy. *Br Med J*, 1974; **2**: 481–2.
- Warrington RJ, Hogg GR, Paraskevas F, Tse KS. Insidious rifampicin-associated renal failure with light-chain proteinuria. *Arch Intern Med*, 1977; **137**: 927–30.

## 9. ADRENAL CRISIS

- Elansary EH, Earis JE. Rifampicin and adrenal crisis. *Br Med J*, 1983; **286**: 1861–2.

**Ethionamide and prothionamide**

For a general review of toxicity, see: British Tuberculosis Association Report 'A comparison of the toxicity of prothionamide and ethionamide'. *Tubercle*, 1968; **49**: 125–35.

## 1. PERIPHERAL NEUROPATHY

- Clarke GBM, O'Hea AJ. Chronic pulmonary tuberculosis: treatment with ethionamide combined with cycloserine and oxytetracycline. *Br Med J*, 1961; **1**: 636–8.
- Leggat PO. Ethionamide neuropathy. *Tubercle*, 1962; **43**: 95–6.
- Poole GW, Schneeweiss J. Peripheral neuropathy due to ethionamide. *Am Rev Resp Dis*, 1961; **84**: 890–2.
- Schless JM, Allison RF, Inglis RM, White EF, Topperman S. The use of ethionamide in combined drug regimens in the re-treatment of isoniazid-resistant pulmonary tuberculosis. *Am Rev Resp Dis*, 1965; **91**: 728–37.

## 2. HEPATIC DYSFUNCTION

- Clarke GBM, O'Hea AJ. Chronic pulmonary tuberculosis: treatment with ethionamide combined with cycloserine and oxytetracycline. *Br Med J*, 1961; **1**: 636–8.
- Conn HO, Binder HJ, Orr HD. Ethionamide-induced hepatitis. *Am Rev Resp Dis*, 1964; **90**: 542–52.
- Edge JR, Weber JCP. Ethionamide (1314 TH) and viomycin in the treatment of resistant pulmonary tuberculosis. *Tubercle*, 1960; **41**: 424–9.
- Gupta DK, Mital OP, Agarwala MC. Hepatic injury due to ethionamide (1314-TH) and prothionamide (1321-TH). *J Assoc Physicians India*, 1975; **23**: 147–51.
- Hollinrake K. Acute hepatic necrosis associated with ethionamide. *Br J Dis Chest*, 1968; **62**: 151–4.
- Lees AW. Jaundice due to ethionamide. *Br J Dis Chest*, 1963; **57**: 158–61.
- Moulding TS, Jr, Goldstein S. Hepatotoxicity due to ethionamide. *Amer Rev Resp Dis*, 1962; **86**: 252–5.
- Pernod J. Hepatic tolerance of ethionamide. *Am Rev Resp Dis*, 1965; **92**: 39–42.
- Phillips S, Trevathan RD. Serum glutamic oxalacetic transaminase elevation and possible hepatotoxicity accompanying the administration of ethionamide. *Am Rev Resp Dis*, 1962; **86**: 268–9.
- Phillips S, Tashman H. Ethionamide jaundice. *Am Rev Resp Dis*, 1963; **87**: 896–7.
- Schless JM, Allison RF, Inglis RM, White EF, Topperman S. The use of ethionamide in combined drug regimens in the re-treatment of isoniazid-resistant pulmonary tuberculosis. *Am Rev Resp Dis*, 1965; **91**: 728–37.
- Somner AR, Brace AA. Changes in serum transaminase due to prothionamide. *Tubercle*, 1967; **48**: 137–43.

## 3. THYROID ENLARGEMENT/HYPOTHYROIDISM

- Moulding T, Fraser R. Hypothyroidism related to ethionamide. *Am Rev Resp Dis*, 1970; **101**: 90–4.
- Schless JM, Allison RF, Inglis RM, White EF, Topperman S. The use of ethionamide in combined drug regimens in the re-treatment of isoniazid-resistant pulmonary tuberculosis. *Am Rev Resp Dis*, 1965; **91**: 728–37.

## 4. HYPOGLYCAEMIA

- Cameron SJ, Crompton GK. Severe hypoglycaemia in the course of treatment with streptomycin, isoniazid and ethionamide. *Tubercle*, 1967; **48**: 307–10.

## 5. PSYCHOSIS

- Lansdown FS, Beran M, Litwak T. Psychotic reaction during ethionamide therapy. *Am Rev Resp Dis*, 1967; **95**: 1053–5.
- Narang RK. Acute psychotic reaction probably caused by ethionamide. *Tubercle*, 1972; **53**: 137–8.
- Swash M, Roberts AH, Muraghan DJ. Reversible pellagra-like encephalopathy with ethionamide and cycloserine. *Tubercle*, 1972; **53**: 132–6.

## 6. GYNAECOMASTIA

- Clarke GBM, O'Hea AJ. Chronic pulmonary tuberculosis: treatment with ethionamide combined with cycloserine or oxytetracycline. *Br Med J*, 1961; **1**: 636–8.
- Kher HL, Rastogi DS, Krishna K *et al*. Ethionamide toxicity amongst service personnel. *Med J Armed Forces India*, 1978; **34**: 60–6.



## 7. ALOPECIA

- Gupta PK, Sharma GS, Jain NK, Kumar P. Ethionamide induced alopecia. *Indian J Tuberc*, 1981; **28**: 216–17.
- Kher HL, Rastogi DS, Krishna K *et al.* Ethionamide toxicity amongst service personnel. *Med J Armed Forces India*, 1978; **34**: 60–6.
- Mital OP, Gupta DK. Alopecia due to ethionamide. *Indian J Tuberc*, 1975; **22**: 121–2.

**Thiacetazone (TBI)**

For general reviews of adverse reactions to thiacetazone, see: (1) Miller AB, Nunn AJ, Robinson DK, Ferguson GC, Fox W, Tall R. A second international co-operative investigation into thiacetazone side-effects. *Bull WHO*, 1970; **43**: 107–25, and 1972; **47**: 211–27. (2) Miller AB, Fox W, Tall R. An international co-operative investigation into thiacetazone (thioacetazone) side-effects. *Tubercle*, 1966; **47**: 33–73. (3) Report of Singapore Tuberculosis Service/Brompton Hospital/British Medical Research Council Investigation. *Tubercle*, 1971; **52**: 88–116.

## I. HYPERSENSITIVITY SKIN REACTIONS

- Coetzee T. Side effect of thiacetazone. *S Afr Med J*, 1980; **57**: 110.
- East African and British Medical Research Council co-operative investigation. *Tubercle*, 1960; **41**: 399–423.
- Ferguson GC, Nunn AJ, Fox W, Miller AB, Robinson DK, Tall R. A second international co-operative investigation into thiacetazone side-effects. *Tubercle*, 1971; **52**: 166–81.
- Handa F, Kumar K, Rani R. Toxic epidermal necrolysis due to thiacetazone. *Indian J Tuberc*, 1974; **21**: 36–8.
- Harland RD. Stevens-Johnson syndrome with unusual skin features occurring in two patients undergoing treatment for pulmonary tuberculosis with thiosemicarbazone. *Tubercle*, 1962; **43**: 189–91.
- Hussain SA, Saksena HC, Kothari RP. Stevens-Johnson syndrome due to thiacetazone. *J Indian Med Assoc*, 1973; **60**: 57–9.
- Kanwar AJ, Singh OP. Toxic epidermal necrolysis—drug induced (report of 2 cases). *Indian J Dermatol*, 1976; **21**: 73–77.
- Katoch K, Ramu G, Ramanathan U. Toxic epidermal necrolysis (Lyell syndrome): a case report. *Lepr India*, 1983; **55**: 133–5.
- Lowe J. The treatment of leprosy with TBI/698. A report based on 38 months' experience. *Lepr Rev*, 1954; **25**: 186–99.
- Mani MZ, Rajan MV, Mathew M, Singh CM. Lichen planus like lesions caused by thiacetazone. *Indian J Dermatol Venereol Lepr*, 1979; **45**: 455–8.
- Moore W. Stevens-Johnson syndrome, erythema multiforme pluriorificialis, in association with the administration of thiosemicarbazone. *Tubercle*, 1960; **41**: 448–9.
- Naraq S, Temu P. Thiacetazone skin reaction in Papua New Guinea. *Med J Aust*, 1980; **1**: 480–1.
- Pearson CA. Thiacetazone toxicity in the treatment of tuberculosis patients in Nigeria. *J Trop Med Hyg*, 1978; **81**: 238–42.
- Purohit SD, Sharma GS, Dhariwal ML. Stevens-Johnson syndrome with thiacetazone. *J Assoc Physicians India*, 1976; **24**: 625–7.
- Short GM. Side-effect of thiacetazone. *S Afr Med J*, 1980; **58**: 5–6.
- White G de L. Side effect of thiacetazone. *S Afr Med J*, 1979; **56**: 981. (With a colour photo of toxic epidermal necrolysis).

2. BLOOD

(a) *Haemolysis*

- Lowe J. The treatment of leprosy with TBI/698. A report based on 38 months' experience. *Lepr Rev*, 1954; **26**: 186–99.
- Masel MA, Johnston NG. Haemolytic anaemia in a patient taking thiacetazone. *Med J Aust*, 1968; **2**: 840–3.
- Mertens A, Bunge R. The present status of the chemotherapy of tuberculosis with Conteben, a substance of the thiosemicarbazone series. *Am Rev Tuberc*, 1950; **61**: 20–38.
- Pines A. Thiacetazone toxicity in British patients. *Tubercle*, 1964; **45**: 188–91.

(b) *Aplastic Anaemia*

- Jaliluddin, Mohsini AA. Fatal aplastic anaemia due to thiacetazone toxicity. *J Indian Med Assoc*, 1981; **77**: 176–7.
- Kanyerezi BR. Red blood cell aplasia due to thiacetazone—a case report. *E Afr Med J*, 1971; **48**: 263–5.

(c) *Neutropenia/Agranulocytosis*

- East African and British Medical Research Council co-operative investigation. *Tubercle*, 1960; **41**: 399–423.
- Hinshaw HC, McDermott W. Thiosemicarbazone therapy of tuberculosis in humans. *Am Rev Tuberc*, 1950; **61**: 145–57.
- Lowe J. The treatment of leprosy with TBI/698. A report based on 38 months' experience. *Lepr Rev*, 1954; **26**: 186–99.
- Lowe J. Acute agranulocytosis caused by TBI/698 (para-acetamidobenzaldehyde thiosemicarbazone). *Lepr Rev*, 1952; **23**: 109–14.
- Mertens A, Bunge R. The present status of the chemotherapy of tuberculosis with Conteben, a substance of the thiosemicarbazone series. *Am Rev Tuberc*, 1950; **61**: 20–38.
- Pines A. Thiacetazone toxicity in British patients. *Tubercle*, 1964; **45**: 188–91.

3. HEPATIC DYSFUNCTION

- East African and British Medical Research Council co-operative investigation. *Tubercle*, 1960; **41**: 399–423.
- Lowe J. The treatment of leprosy with TBI/698. A report based on 38 months' experience. *Lepr Rev*, 1954; **26**: 186–99.
- Pines A. Thiacetazone toxicity in British patients. *Tubercle*, 1964; **45**: 188–91.
- Webb AH. A thiacetazone toxicity trial in Sarawak. *NZ Med J*, 1973; **78**: 409–12.

4. OTOTOXICITY

The capacity of thiacetazone to enhance streptomycin's ototoxicity has been reported in *Tubercle*, 1966; **47**: 33–73, a paper mentioned at the head of this Section under 'general reviews of adverse reactions'. See also: Pearson CA. Thiacetazone toxicity in the treatment of tuberculosis patients in Nigeria. *J Trop Med Hyg*, 1978; **81**: 238–42.